0JV0 Stock Chart & Stats
€1.22
€0.03(2.86%)
At close: 4:00 PM EDT
€1.22
€0.03(2.86%)
Day’s Range― - ―
52-Week Range€0.44 - €2.62
Previous CloseN/A
Volume0.00
Average Volume (3M)35.00
Market Cap
€60.31M
Enterprise Value€154.77
Total Cash (Recent Filing)€74.80M
Total Debt (Recent Filing)€2.33M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Sep 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding49,678,562
10 Day Avg. Volume6
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.91Price Target Upside302.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.27
Revenue Forecast (FY)€87.62K
Bulls Say, Bears Say
Bulls Say
Clinical-stage TransitionAdvancing IBIO-600 into first-in-human Phase 1 moves the company from preclinical toward clinical validation, materially reducing technical risk for that asset. Clinical entry can unlock partner interest, milestone funding, and clearer development milestones that support multi-quarter strategic planning.
Differentiated Obesity ProgramIBIO-610’s preclinical profile—near-complete Activin E suppression, fat-selective loss, and beneficial combo data with semaglutide—suggests a potentially first-in-class, infrequently dosed therapy. If replicated clinically, this could create durable competitive differentiation in a large, structurally growing obesity therapeutics market.
Experienced Board AdditionAdding a seasoned biotech executive with deep R&D and go-to-market experience strengthens governance and execution capacity during the transition to clinical-stage operations. Such experience can improve trial design, partner discussions, and strategic decision-making over multiple quarters.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flows indicate the business cannot self-fund development; this creates an ongoing dependency on external capital. Over a multi-quarter horizon, cash burn elevates refinancing and execution risk, potentially forcing dilution or delays in advancing programs if funding gaps arise.
Minimal Product RevenueNear-zero revenue and negative margins mean the company lacks recurring product cash flows to offset R&D spend. This structural revenue gap limits internal reinvestment capacity and makes long-term growth contingent on licensing, partnerships, or successful clinical outcomes rather than operating leverage.
Financing / Dilution RiskAlthough leverage is low, the balance sheet history and current cash burn imply reliance on equity raises to fund operations. Recurrent capital raises can dilute shareholders and create execution uncertainty; this structural funding model is a persistent risk until operations generate sustainable cash.
Ibio News
0JV0 FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was €0.44 and its highest was €2.62 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is €60.31M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Sep 29, 2026 which is in 53 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on May 12, 2026. The company reported -€0.061 earnings per share for the quarter, missing the consensus estimate of -€0.055 by -€0.006.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 49,678,562 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -€0.061 in its last earnings report, missing expectations of -€0.055. Following the earnings report the stock price went down -6.756%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in DE:0JV0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.91 (302.61% Upside)
€4.91 (302.61% Upside)
Blogger Sentiment
Bullish
DE:0JV0 Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
97.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
349.32%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
0JV0 Stock 12 Month Forecast
Average Price Target
€4.91
▲(302.61% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―